E.S. KLYACHINA, O.G. SMOLENSKAYA, S.S. VEDENSKAYA

 Ural State Medical University, Ekaterinburg

 Contact details:

Klyachina E.S. — Assistant Lecturer of the Department of Faculty Therapy, Endocrinology, Allergology and Immunology

Address: 3 Repina St., Ekaterinburg, Russian Federation, 620028, tel.: 89049856095, e-mail: katrina.s.sharm@gmail.com

At the moment, there is a lot of data demonstrating the effectiveness of anticoagulants in the acute period of COVID-19; as for their effectiveness in patients after discharge, there are relatively few data, especially in patients with concomitant cardiological pathology.

The purpose — is to evaluate the relationship of taking anticoagulants, within one month after discharge, with the development of cardiovascular events and deaths in patients with cardiovascular pathology during 3 months of follow-up.

Material and methods. A retrospective, cohort, observational study of 317 patients who had COVID-19 and had a history (before COVID-19) of cardiovascular pathology was conducted.

Results. Within three months after discharge from the hospital, 15 (4.73%) cardiovascular events were registered. The frequency of arterial thrombotic complications was 3.79% (n = 12), venous thrombotic complications 0.95% (n = 3). All cardiovascular events were reported in patients not using anticoagulants (n = 15; 6.28%), p = 0.026. When analyzing concomitant cardiovascular pathology in patients with registered events, it was revealed that the incidence of atrial fibrillation and ischemic stroke in their anamnesis was statistically significantly higher (33.33 and 40%), relative to the comparison group (10.03 and 7.9%; p = 0.002; p = 0.001, respectively).

Conclusions. The use of anticoagulants in patients with cardiovascular pathology during treatment in a COVID hospital and within one month after discharge was associated with a significant decrease in thromboembolic events over 3 months of follow-up. Predictors of thromboembolic events in patients with cardiovascular pathology and those who have had COVID-19 are: senior age; atrial fibrillation and ischemic stroke in the anamnesis.

Key words: COVID-19, complications of COVID-19, anticoagulants.

REFERENCES

1. Middeldorp S., Coppens M., van Haaps T.F. Incidence of venous thromboembolism in hospitalized patients with COVID-19. Journal of Thrombosis and Haemostasis, 2020, vol. 18 (8), pp. 1995–2002.
2. Lodigiani C., Iapichino G., Carenzo L. et al. Humanitas COVID-19 Task Force. Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in Milan, Italy. Thrombosis Research, 2020, vol. 191, rr. 9–14.
3. Klok F.A, Kruip M.J.H.A., van der Meer N.J.M. et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thrombosis Research, 2020,vol. 191, pp. 145–147.
4. Nadkarni G.N., Lala A., Bagiella E. Anticoagulation, bleeding, mortality, and pathology in hospitalized patients with COVID-19. Journal of the American College of Cardiology, 2020, vol. 76, pp. 1815–1826.
5. Giannis D., Allen S.L., Davidson A. et al. Thromboembolic outcomes of hospitalized COVID-19 patients in the 90-day post-discharge period: early data from the Northwell CORE-19 Registry. Blood Journal, 2020, vol. 136, rr. 33–34.
6. Patell R., Bogue T., Koshy A. et al. Post-discharge thrombosis and hemorrhage in patients with COVID-19. Blood Journal, 2020, vol. 136, pp. 1342–1346.
7. Cummings M.J., Baldwin M.R., Abrams D. et al. Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study. Lancet, 2020, vol. 395 (10239), rr. 1763–1770.
8. Suleyman G., Fadel R.A., Malette K.M. et al. Clinical Characteristics and Morbidity Associated with Coronavirus Disease 2019 in a Series of Patients in Metropolitan Detroit. JAMA Network Open, 2020, vol. 3 (6), p. e2012270.
9. Bae S., Kim S.R., Kim M.N., et.al. Impact of cardiovascular disease and risk factors on fatal outcomes in patients with COVID-19 according to age: a systematic review and meta-analysis. Heart, 2021, vol. 107 (5), rr. 373–380.
10. Wu Z., McGoogan J.M. Characteristics of and Important Lessons from the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases from the Chinese Center for Disease Control and Prevention. JAMA, 2020, vol. 323 (13), rr. 1239–1242.
11. Spyropoulos A.C., Anderson F.A. Jr, Fitzgerald G. et al. IMPROVE Investigators. Predictive and associative models to identify hospitalized medical patients at risk for VTE. Chest, 2011, vol. 140 (3), rr. 706–714.
12. Hull R.D., Merali T., Mills A. et al. Venous thromboembolism in elderly high-risk medical patients: time course of events and influence of risk factors. Clinical and Applied Thrombosis Hemostasis, 2013, vol. 19, pp. 357–362.
13. Spyropoulos A.C., Ageno W., Albers G.W. et al. Post-discharge prophylaxis with rivaroxaban reduces fatal and major thromboembolic events in medically ill patients. Journal American College Cardiology, 2020, vol. 75, pp. 3140–3147.
14. Ramacciotti E., Barile Agati L., Calderaro D. et. al. MICHELLE investigators. Rivaroxabanversus no anticoagulation for post-discharge thromboprophylaxis after hospitalisation for COVID-19 (MICHELLE): an open-label, multicentre, randomised, controlled trial. Lancet, 2022, vol. 399 (10319), rr. 50–59.
15. Krantz M.J., Kaul S. The ATLAS ACS 2-TIMI 51 trial and the burden of missing data: (Anti-Xa Therapy to Lower Cardiovascular Events in Addition to Standard Therapy in Subjects with Acute Coronary Syndrome ACS 2-Thrombolysis In Myocardial Infarction 51). Journal American College Cardiology, 2013, vol. 62 (9), rr. 777–781.
16. Branch K.R., Probstfield J.L., Eikelboom J.W. et al. Rivaroxaban with or Without Aspirin in Patients with Heart Failure and Chronic Coronary or Peripheral Artery Disease. Circulation, 2019, vol. 140 (7), rr. 529–537.
17. Poissy J., Goutay J., Caplan M. et al. Lille ICU Haemostasis COVID-19 Group. Pulmonary embolism in patients with COVID-19: awareness of an increased prevalence. Circulation, 2020, vol. 142 (2), rr. 184–186.
18. Wilterdink J.L., Easton J.D. Vascular event rates in patients with atherosclerotic cerebrovascular disease. Archives of Neurology, 1992, vol. 49 (8), pp. 857–863.